CVSI CV Sciences (CVSI) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001510964
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about CVSI
Insiders, 180 days
+$114.8K net bought
1 buyer
CV Sciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, CV Sciences, Inc. insiders bought a net $114.8K of stock across 10 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Aug 4, 2026.
- -50.0% median (-43.6% mean) 90-day return after 7 previous buys.
- The trade is 0.4% of the 26,648,711 shares held after it.
- No other insider bought within 30 days.
Insider activity: Insider CHEEVER CHARLIE E III bought about $1.9K of CVSI on Aug 7, 2026.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Jul 31, 2026.
- -50.0% median (-43.6% mean) 90-day return after 7 previous buys.
- The trade is 0.4% of the 26,553,857 shares held after it.
- No other insider bought within 30 days.
Insider activity: Insider CHEEVER CHARLIE E III bought about $2.2K of CVSI on Aug 4, 2026.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Jul 29, 2026.
- -50.0% median (-43.6% mean) 90-day return after 7 previous buys.
- The trade is 6.5% of the 26,445,857 shares held after it.
- No other insider bought within 30 days.
Insider activity: Insider CHEEVER CHARLIE E III bought about $34.6K of CVSI on Jul 31, 2026.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jul 28, 2026.
- -50.0% median (-41.7% mean) 90-day return after 6 previous buys.
- The trade is 0.2% of the 24,715,857 shares held after it.
- No other insider bought within 30 days.
Insider activity: Insider CHEEVER CHARLIE E III bought about $1.2K of CVSI on Jul 29, 2026.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Jul 24, 2026.
- -50.0% median (-40.0% mean) 90-day return after 5 previous buys.
- The trade is 7.4% of the 24,655,857 shares held after it.
- No other insider bought within 30 days.
Insider activity: Insider CHEEVER CHARLIE E III bought about $36.6K of CVSI on Jul 28, 2026, the largest insider purchase at the company on our record.10 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$114.8K over 180 days
+$38.7K over 90 days · +$114.8K of it by a 10%+ holder
more than 77% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-12.2% year over year
below 66% of Pharma & Biotech
Margin
-6.9% net margin
more than 66% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 94% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CVSI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-77.5%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CVSI: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in CVSI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CVSI planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$419.0K
$423.1K
$308.0K
n/a
n/a
2024
$457.7K
$241.3K
$343.3K
+0%
n/a
2023
$403.2K
$314.0K
$273.0K
+33%
n/a
2022
$299.0K
$245.3K
$210.5K
-75%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $114.8K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
CVSI financials
Revenue growth
-12.2%
XBRL, annual
Net margin
-6.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$12.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CVSI
| FY Dec 2025 | $13.8M |
| FY Dec 2024 | $15.7M |
| FY Dec 2023 | $16.0M |
| FY Dec 2022 | $16.2M |
| FY Dec 2021 | $20.0M |
| Jun 2026 | $3.0M |
| Mar 2026 | $3.2M |
| Dec 2025 | $3.3M |
| Sep 2025 | $3.3M |
| Jun 2025 | $3.6M |
| Mar 2025 | $3.6M |
| Dec 2024 | $3.9M |
| Sep 2024 | $3.9M |
At each fiscal year end
Single quarter
Net margin, TTM
-15.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CVSI
| FY Dec 2025 | -6.9% |
| FY Dec 2024 | -15.2% |
| FY Dec 2023 | +19.4% |
| FY Dec 2022 | -50.7% |
| FY Dec 2021 | -77.6% |
| Jun 2026 | -26.0% |
| Mar 2026 | -20.1% |
| Dec 2025 | -6.2% |
| Sep 2025 | -11.7% |
| Jun 2025 | -7.2% |
| Mar 2025 | -3.0% |
| Dec 2024 | -18.7% |
| Sep 2024 | -11.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$522.0K
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CVSI
| FY Dec 2025 | -$516.0K |
| FY Dec 2024 | -$879.0K |
| FY Dec 2023 | $2.3M |
| FY Dec 2022 | -$1.9M |
| FY Dec 2021 | -$7.5M |
| Jun 2026 | $13.0K |
| Mar 2026 | $98.0K |
| Dec 2025 | -$363.0K |
| Sep 2025 | -$270.0K |
| Jun 2025 | $238.0K |
| Mar 2025 | -$121.0K |
| Dec 2024 | -$182.0K |
| Sep 2024 | -$122.0K |
At each fiscal year end
Single quarter
Debt to equity
0.01x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity CVSI
| FY Dec 2025 | 1.12x |
| FY Dec 2024 | 0.38x |
| FY Dec 2023 | 0.11x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.09x |
| Jun 2026 | 0.01x |
| Mar 2026 | 0.05x |
| Dec 2025 | 1.12x |
| Sep 2025 | 0.62x |
| Jun 2025 | 0.68x |
| Mar 2025 | 0.67x |
| Dec 2024 | 0.38x |
| Sep 2024 | 0.14x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-27.33x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt CVSI
| FY Dec 2025 | -0.25x |
| FY Dec 2024 | -1.27x |
| FY Dec 2023 | 7.27x |
| FY Dec 2022 | -6.08x |
| FY Dec 2021 | -24.15x |
| Jun 2026 | -27.33x |
| Mar 2026 | -3.12x |
| Dec 2025 | -0.25x |
| Sep 2025 | -0.23x |
| Jun 2025 | -0.06x |
| Mar 2025 | -0.33x |
| Dec 2024 | -1.27x |
| Sep 2024 | -2.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-118.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CVSI
| FY Dec 2025 | -58.7% |
| FY Dec 2024 | -101.9% |
| FY Dec 2023 | +291.8% |
| FY Dec 2022 | -593.9% |
| FY Dec 2021 | -210.8% |
| Jun 2026 | -118.9% |
| Mar 2026 | -88.0% |
| Dec 2025 | -58.7% |
| Sep 2025 | -79.2% |
| Jun 2025 | -72.0% |
| Mar 2025 | -88.2% |
| Dec 2024 | -101.9% |
| Sep 2024 | -89.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-27.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CVSI
| FY Dec 2025 | -12.9% |
| FY Dec 2024 | -28.0% |
| FY Dec 2023 | +28.3% |
| FY Dec 2022 | -53.3% |
| FY Dec 2021 | -63.9% |
| Jun 2026 | -27.7% |
| Mar 2026 | -20.6% |
| Dec 2025 | -12.9% |
| Sep 2025 | -19.2% |
| Jun 2025 | -18.4% |
| Mar 2025 | -23.1% |
| Dec 2024 | -28.0% |
| Sep 2024 | -28.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CVSI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-50.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CVSI
| FY Dec 2025 | -24.9% |
| FY Dec 2024 | -89.3% |
| FY Dec 2023 | +268.0% |
| FY Dec 2022 | -452.4% |
| FY Dec 2021 | -185.4% |
| Jun 2026 | -50.7% |
| Mar 2026 | -39.4% |
| Dec 2025 | -24.9% |
| Sep 2025 | -46.7% |
| Jun 2025 | -43.4% |
| Mar 2025 | -62.2% |
| Dec 2024 | -89.3% |
| Sep 2024 | -83.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CVSI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 2.00x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.4M
market value at close 2026-10-27 on 2026-08-11 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2022-12-31
Enterprise value CVSI
| FY Dec 2025 | $12.1M |
| FY Dec 2024 | $5.6M |
| FY Dec 2023 | $5.9M |
| FY Dec 2022 | $4.2M |
| FY Dec 2021 | $12.2M |
| Jun 2026 | $3.5M |
| Mar 2026 | $5.3M |
| Dec 2025 | $12.1M |
| Sep 2025 | $7.7M |
| Jun 2025 | $8.0M |
| Mar 2025 | $6.2M |
| Dec 2024 | $5.6M |
| Sep 2024 | $8.7M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-25.7%
TTM free cash flow over market value at close 2026-10-27
FCF yield CVSI
| FY Dec 2025 | -4.7% |
| FY Dec 2024 | -15.9% |
| FY Dec 2023 | +36.4% |
| FY Dec 2022 | -41.9% |
| FY Dec 2021 | -56.6% |
| Jun 2026 | -12.8% |
| Mar 2026 | -5.1% |
| Dec 2025 | -4.7% |
| Sep 2025 | -4.5% |
| Jun 2025 | -2.5% |
| Mar 2025 | -8.7% |
| Dec 2024 | -15.9% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CVSI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $13.8M | $15.7M | $16.0M | $16.2M |
| Gross profit | $6.8M | $7.2M | $7.1M | $5.5M |
| Operating income | -$470.0K | -$2.2M | $3.4M | -$6.8M |
| Net income | -$958.0K | -$2.4M | $3.1M | -$8.2M |
| EPS (diluted) | -0.01 | -0.01 | 0.02 | -0.07 |
| Operating cash flow | -$407.0K | -$861.0K | $2.3M | -$1.9M |
| Cash | n/a | n/a | n/a | $611.0K |
| Long-term debt | $387.0K | $0 | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
CVSI Stock Sonar score 5/7 axes
Find similar shapesCompareCVSI ranks highest on risk and compliance (96th percentile) and insider conviction (66th), and lowest on growth (34th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CVSI filings, in plain words
Are CV Sciences insiders buying or selling CVSI?
In the 180 days to 2026-10-28, CV Sciences insiders were net buyers, a net $114.8K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, CV Sciences insiders were net buyers of CVSI, a net $114.8K across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $114.8K, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
